3Kagoya Y, Seo S, Nannya Y, et al. Hypedipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. Clin Transplant,2012,26 ( 2 ) : E168-175.
4Matthan N R, Pencina M, La Rocque J M, et al. Alterations in choles-terol absorption/synthesis markers characterize Framingham off- spring study participants with CHD. J Lipid Res, 2009,50 ( 9 ) : 1927-1935.
5Okada K, Yagyu H, Kotani K, et al. Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. Endocr J,2010,57(10) :903-908.
6Niesor E J, Chaput E, Staempfli A, et al. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis,2011,219 (2) :761- 767.
7Sheth S G, Gordon F D, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med,1997,126(20) : 1603-1605.
8Lieber C S. New concepts of the pathogeneisi of alcoho liver disease lead to novel treatments. Curr Gastorenterol Rep ,2009,6 (16) :64.
